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We have developed a contemporary, nationwide, prospective cohort of patients with so-called high-risk CV diseases (stroke and MI, as well as AF) in Japan, namely, J-TRACE. 24 Baseline characteristics of the 8,087 recruited patients have been published. 25 In the present study, we focused on the 1-year events rate of all-cause mortality, stroke, and MI in patients recruited in the J-TRACE.
Methods
Details of the study design, including rationale, strategy for selecting participating investigators (physicians), and recruitment of patients to generate a clinical database that represents real-world clinical practice in Japan, have been published elsewhere. 24- 26 Briefly, we divided Japan into 10 regions. We then selected region coordinators of cardiologists and stroke specialists from all 10 regions. Every region coordinator nominated the study hospitals and participating clinics as well as study investigators to represent real-world medical practice in each region.
Briefly, consecutive outpatients aged 20-90 years with a history of stroke, MI, and/or AF were enrolled. Definitions of stroke, MI, and AF were described as previously published. 24 Of note, both ischemic and hemorrhagic stroke patients diagnosed on computed tomography (CT) or magnetic resonance imaging (MRI) were included. According to the definition, patients with chronic, persistent, or paroxysmal AF diagnosed on electrocardiography can be enrolled. 24 Indeed, all the AF patients enrolled were those with non-valvular AF. 23 Any acute-phase patients, defined as patients requiring hospitalization, were excluded because the CV event risk in these acute phase patients is known to be markedly higher than that of stable outpatients. 19,27-29 Patients were enrolled from 201 sites to represent real-world medical care in Japan. The study protocol was approved by the institutional review board at each participating institute and signed informed consent was obtained from all patients. Data were collected centrally via use of a Web-based, standardized, electronic case report form completed by participating physicians. Finally, a total of 8,087 patients were recruited. 25 Baseline characteristics of all patients recruited in this registry have been published elsewhere. 23 In spite of repeated systemic alert, 1-year event information was not entered for all patients at the time of database lock. Thus, the 1-year follow up rate in the present study is not 100%. Risk factors such as hypertension, diabetes mellitus, hypercholesterolemia, were defined according to practice guidelines as previously published. 23 We assessed the distribution of the congestive heart failure, hypertension, aging, diabetes mellitus, and history of stroke or transient ischemic attack (CHADS2) score in that group and its relation to outcome.
A 2-year follow-up was planned for recruited patients. The primary outcome measure was a composite of all-cause death, non-fatal symptomatic stroke, and non-fatal MI. Non-fatal stroke was defined as acute onset of focal neurological manifestation and the responsible lesion was confirmed on brain CT or MRI. Non-fatal MI was defined as increased biochemical markers such as creatinine phosphokinase-MB and troponin, and either prolonged ischemic symptoms (lasting for >30 min) or newly developed ischemic electrocardiographic changes, including abnormal Q waves and ST-segment elevation or depression. Secondary outcomes were all-cause death, non-fatal MI, non-fatal stroke separately, and any dropouts from the study, and the incidence of cerebral hemorrhage, any other bleedings, or serious adverse experiences leading to admission. 24 If the patients died during follow-up, the reason for death for each patient was described in detail in the case report form by the investigators. All outcomes were defined by the investigators and were not adjudicated by a specific committee. In the present study, all events occurring in each patient from study entry to 12 months were considered as '1-year events'.
Methods of data analysis have already been published. 24 Briefly, all relevant data were presented using means and standard deviations for continuous data, and as counts or percentages for categorical data. The event rate was expressed as number of events per 100 person-years. When multiple events occurred in the same patients during the follow-up period, those events were regarded as multiple independent events. Statistical analysis was conducted with R 2.13.0 (R Foundation for Statistical Computing, Department of Statistics and Mathematics, Wirtschafts Universitat, Wien, Austria). The 95% confidence interval (CI) was calculated by the normal approximation of Poisson distribution that the number of events per year was assumed to follow. Cumulative incidence curves were constructed for primary endpoints using the Kaplan -Meier approach.
Results
Follow-up Rate, Risk-Factor Profile, and Drug Usage Of the 8,087 patients enrolled from Japan nationwide in the J-TRACE registry, 1-year event data were available for Table 2 . Calcium-channel blockers (calcium antagonists) were the most frequently used anti-hypertensive drugs in all disease categories. Approximately half of the patients with diabetes were treated with oral glucose-lowering agents. Statins were most frequently used in MI patients with hypercholesterolemia (74.9%), while their use in patients with stroke or AF patients was lower (60.7% and 57.3%, respectively). Aspirin use was 82.6% in MI patients and 46.0% in stroke patients. Use of warfarin was 70.0% in AF patients and was less frequent in stroke or MI patients.
Primary Endpoint
The cumulative event rate of the combined endpoint of allcause mortality, non-fatal MI, or non-fatal stroke is shown as a Kaplan -Meier curve (Figure 1) . Indeed, 3.53 per 100 person-years (95%CI: 3.11-3.99 per 100 person-years) of patients experienced the primary endpoint within 1 year. Details of secondary endpoints are summarized in Tables 3,4 , respectively. Rates of death from stroke and from MI are also shown in Table 3 . Most frequent cause of death within 1 year (1.35 per 100 person-years; 95%CI: 1.10-1.65) in the J-TRACE was neither death from stroke, MI, nor major bleeding events. Indeed, the rates of death from stroke and MI were only 0.15 per 100 person-years (95%CI: 0.08-0.27) and 0.06 per 100 person-years (95%CI: 0.02-0.14), respectively. The rate of death from serious bleeding was 0.05 per 100 person-years (95%CI: 0.01-0.14). The most frequent cause of death in the J-TRACE was classified as 'others'. As shown in Table 4 , the most frequent non-fatal events in J-TRACE were stroke. Indeed, 1.85 events per 100 personyears (95%CI: 1.55-2.19) recruited in J-TRACE experienced non-fatal stroke within 1 year. The stroke rate was the highest among the stroke patients (2.95 per 100 person-years; 95%CI: 2.39-3.60) followed by the AF patients As shown in Figure 2 , the stroke patients experienced the highest rates of the primary endpoint and of non-fatal stroke, followed by the AF and MI patients. In general, the rate of non-fatal stroke was higher in the stroke patients than in the AF patients.
As shown in Figure 3 , the CHADS2 score is a useful predictor of the primary endpoint, not only in AF patients, but also in stroke or MI patients. Although all-cause mortality and stroke rates were well-associated with the CHADS2 score, the rate of non-fatal MI was not (Figure 4 ) in all patients recruited in the J-TRACE. Rates of all-cause death (red), non-fatal stroke (blue), and non-fatal myocardial infarction (MI; green) within 1 year in each CHADS2 score category. Results are shown as number of events per 100 person-years. CHADS2, congestive heart failure, hypertension, aging, diabetes mellitus, and history of stroke or transient ischemic attack. One-Year Events in J-TRACE Discussion J-TRACE is a registry of stable outpatients, whose data have been used to generate the likelihood of high-risk CV events in real-world medical practice, who have a history of MI, stroke or who have AF, recruited nationwide from Japan. Approximately 3.5 patients per 100 person-years experienced the predefined primary endpoint of death, MI, or stroke within 1 year even though they are apparently stable outpatients with no limitation of treatment. This value is relatively lower than that reported in a similar global registry, 19 but is equivalent to the value reported in a Japanese sub-study of that global registry. 30 As shown in the previous studies, most primary endpoint events were stroke rather than MI. 30 The rate of symptomatic MI was <0.5 per 100 person-years, even in patients with a history of MI.
The present J-TRACE study confirmed the higher rate of CVD events (stroke) compared with CAD events (CV death and MI) in Japanese patients. It is important to note that the rate of stroke was higher than that of MI even among patients initially recruited with a history of MI. Although the recurrence rate for stroke was high, stroke patients were not so frequently treated with antiplatelet agents or statins compared to MI patients. The markedly lower use of clopidogrel in this registry reflects the fact that most of the patients were recruited before and soon after registration of clopidogrel. Instead, the use of ticlopidine was relatively common both in the stroke and MI patients. Non-use of anti-hypertensive agents in patients with hypertension was also frequent among the stroke patients compared with the MI patients. Thus, we have to conclude that stroke patients were undertreated compared with MI patients, despite the recurrence rate for stroke being higher in Japan.
Unlike North America and Europe, the most common cause of death in Japan is not CV disease, but cancer. 31, 32 The present J-TRACE results support the great impact of cancer in Japan even in stroke, MI, and AF patients, because at least 34 of the total 98 death events within 1 year were reported as being caused by newly detected cancer according to the investigators' comments. It is also important to note that the rate of serious bleeding events was only <0.2 per 100 person-years in Japan, despite the high incidence of cancer and similar use of anti-thrombotic agents compared with other countries. 16 The present J-TRACE results support the usefulness of risk stratification based upon the CHADS2 score for predicting primary outcome events within 1 year, not only in AF patients but also in non-AF stroke and MI patients. 10 The predictive value of the CHADS2 score, however, is limited in all-cause mortality and stroke. The rate of MI did not correlate with the CHADS2 score, although the total number of events was not high. 10 Because the total number of CV and serious bleeding events was not large enough, we could not estimate the validity of the recently developed, detailed, risk-stratification methods of cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled) -vascular disease, age at 65-74 years and sex category (female) (CHA2DS2-VASc) 12 or the hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly (1 point each) (HAS-BLED) 33 in this registry. Longer follow-up of this registry might be necessary in order to provide this level of detail.
Although J-TRACE is a nationwide registry, representing real-world practice in Japan, it might be argued that the loss to follow-up of approximately 7% of patients could have influenced the present results. In general, a follow-up rate of 93% is sufficiently high, particularly in the case of J-TRACE, where the registry is large and homogenous (Japanese patients living in Japan). We cannot exclude a small margin of error, however, in the estimation of event rates due to the possible influence of the loss of patients to follow-up. The similarity in risk-factor profiles and drug usage between all recruited patients 25 and in those with 1-year data reported in the present study may suggest the absence of systematic bias. Nevertheless, the J-TRACE inclusion criteria for MI and stroke have a restriction only to exclude acute phase inhospital patients, thus there might be a potential heterogeneity among these patient groups. Outcome events were not determined by specific adjudication committees, thus, there might be a redundancy based upon the experience and subspecialty of investigators. There might be redundancy in the rate of death from MI and stroke because, unlike the WHO-MONICA study, 6,7 J-TRACE did not include the specific criteria for the precise definition of death caused by MI and stroke. As previously published, the majority of patients were recruited from hospital by specialists of cardiology and neurology. 23 Thus, J-TRACE might represent the real-world practice in a hospital setting in Japan with a relatively small contribution from clinics and GPs.
We recruited patients with a history of MI, stroke and who had AF (categorized as high-risk CV diseases), even in the outpatient setting. Although they are considered as high-risk CV diseases in clinical practice in the real world, 10 there is substantial heterogeneity in pathophysiology among them. It is interesting to note, however, that the rate of primary endpoints such as stroke are similarly influenced by CHADS2 score in all subcategories of disease at baseline. In the previous studies we demonstrated the heterogeneity and overlap among CAD including MI, CVD including stroke, and peripheral artery diseases. 16,19,21,34, 35 In addition to providing information on the impact of AF on these diseases, 10 we demonstrated the heterogeneity and overlap among these vascular diseases and AF in the present study.
In conclusion, with the use of the large, contemporary, nationwide J-TRACE database, we have found a low annual CV event rate in Japanese patients with a history of stroke, MI, or patients with AF. The rate of stroke was highest among patients with a history of stroke. The rates of all-cause mortality and non-fatal stroke, but not non-fatal MI, were higher in patients with a higher CHADS2 score, in both AF and non-AF patients.
